ASCO GI 2021 | Onvansertib for second-line treatment of KRAS-mutated mCRC

Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, highlights the progress in developing agents targeting the MAP-kinase signaling pathway, including the development of onvasertinib, a polo-like kinase 1 inhibitor currently evaluated in a Phase Ib/II study in combination with FOLFIRI and bevacizumab in patients with KRAS-mutated metastatic colorectal cancer (mCRC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).